NCT07582783 A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
| NCT ID | NCT07582783 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Janssen Research & Development, LLC |
| Condition | Psoriasis |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2028-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2026-05-15 with a primary completion date of 2028-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
Eligibility Criteria
Inclusion criteria: * Has a confirmed diagnosis of moderate-to-severe plaque psoriasis * Participant must sign an informed consent form allowing source data verification in accordance with local requirements * Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments * No previous exposure to biological treatment, including guselkumab (bio-naive patient) * Intended for the treatment with guselkumab according to the approved indication Exclusion criteria: * Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC) * Is pregnant or lactating * Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product. * Currently enrolled in another observational study sponsored or managed by a Johnson \& Johnson company
Contact & Investigator
Johnson & Johnson Romania SRL Clinical Trial
STUDY DIRECTOR
Johnson & Johnson Romania SRL
Frequently Asked Questions
Who can join the NCT07582783 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07582783 currently recruiting?
Yes, NCT07582783 is actively recruiting participants. Contact the research team at Participate-In-This-Study1@its.jnj.com for enrollment information.
Where is the NCT07582783 trial being conducted?
This trial is being conducted at Bârlad, Romania, Brasov, Romania, Bucharest, Romania, Bucharest, Romania and 11 additional locations.
Who is sponsoring the NCT07582783 clinical trial?
NCT07582783 is sponsored by Janssen Research & Development, LLC. The principal investigator is Johnson & Johnson Romania SRL Clinical Trial at Johnson & Johnson Romania SRL. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.